Abstract
To estimate the status of β-cell dysfunction and insulin resistance of breast cancer (BC) patient without history of diabetes mellitus (DM) after systemic treatment through an oral glucose tolerance test (OGTT) and insulin releasing test (IRT). All the 128 BC patients without history of DM after systemic treatment underwent OGTT and IRT test. Fasting and 2-h glucose levels were measured to confirm undiagnosed DM and prediabetes. Insulin sensitivity was estimated by homeostasis model assessment of insulin resistance (HOMA-IR) and Matsuda index and disposition index (IGI/HOMA-IR). Insulin secretion was estimated by the insulinogenic index (IGI) [Δ insulin/Δ glucose (30–0 min)]. Insulin concentrations during the OGTT and IRT at baseline were used to derive the patterns of insulin secretion curve (pattern 1, pattern 2, pattern 3, pattern 4 and pattern 5), which were used to estimate the risk of developing DM. Of 128 BC patients without history of DM after systemic treatment, there were 46 cases (35.9 %) of NGT, 60 cases (46.9 %) of prediabetes and 22 cases (17.2 %) of DM. The BMI of prediabetes and DM were higher than NGT groups with statistical significance. After adjusted for BMI, IGI was significantly lower in DM group but not significantly different between NGT group and prediabetes group. HOMA-IR, Matsuda index and disposition index were significantly different in DM group compared with NGT group and prediabetes and also significantly different between NGT and prediabetes groups. The total rates of patterns 4 and 5 in NGT and prediabetes groups were 15.3 % (10.9 and 4.4 %) and 48.3 % (31.6 and 16.7 %), respectively. β-Cell dysfunction and insulin resistance may appear in BC patients after systemic treatment. BC patients have high risk in development of DM even in NGT and prediabetes groups confirmed by OGTT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Yang W, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.
Ahn J, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091–102.
Buysschaert M, Sadikot S. Diabetes and cancer: a 2013 synopsis. Diabetes Metab Syndr. 2013;7(4):247–50.
Schott S, Schneeweiss A, Sohn C. Breast cancer and diabetes mellitus. Exp Clin Endocrinol Diabetes. 2010;118(10):673–7.
Yerrabothala S, et al. The impact of diabetes mellitus on breast cancer outcomes: a single center retrospective study. Pathol Oncol Res. 2014;20(1):209–14.
Wolf I, et al. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6(2):103–11.
Ji GY, et al. Incidences of diabetes and prediabetes among female adult breast cancer patients after systemic treatment. Med Oncol. 2013;30(3):687.
Wang RJ, et al. Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China. Med Oncol. 2014;31(1):788.
World Health Organization. Definition,diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
Hayashi T, et al. Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. Diabetes Care. 2013;36(5):1229–35.
Utzschneider KM, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32(2):335–41.
Gold HT, et al. Treatment and outcomes in diabetic breast cancer patients. Breast Cancer Res Treat. 2014;143(3):551–70.
Chen X, et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 2010;122(3):823–33.
Malek M, et al. Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol. 2013;2013:636927.
Li G, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783–9.
Acknowledgments
It was supported by National Natural Science Foundation of China (NSFC) (81372851) and through provision of data by the Breast Cancer Center of Chongqing, The First Affiliated Hospital of Chongqing Medical University, Republic of China. The opinions, results and conclusions reported in this article are those of the authors.
Conflict of interest
All the authors declare that there is no conflict of interest associated with this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Lin-jie Lu, Lu Gan, Jin-bo Hu and Liang Ran have contributed equally to this study.
Rights and permissions
About this article
Cite this article
Lu, Lj., Gan, L., Hu, Jb. et al. On the status of β-cell dysfunction and insulin resistance of breast cancer patient without history of diabetes after systemic treatment. Med Oncol 31, 956 (2014). https://doi.org/10.1007/s12032-014-0956-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0956-x